Literature DB >> 12397153

Central motor conduction in patients with anti-ganglioside antibody associated neuropathy syndromes and hyperreflexia.

Y Oshima1, T Mitsui, H Yoshino, I Endo, M Kunishige, A Asano, T Matsumoto.   

Abstract

OBJECTIVES: Several serum antibodies against gangliosides are diagnostically important, particularly in Guillain-Barré syndrome (GBS), Miller Fisher syndrome (MFS), and multifocal motor neuropathy (MMN). Although hyperreflexia is an atypical symptom in these disorders, it has been found in some patients with GBS, MFS, and MMN. The aim of the study was to determine whether hyperreflexia corresponds to corticospinal tract dysfunction in these patients.
METHODS: The study examined central and peripheral motor conduction in patients with hyperreflexia who exhibited acute paralysis (group 1, n=5), acute ataxia and ophthalmoplegia (group 2, n=7), or chronic paralysis with conduction block (group 3, n=2). The clinical symptoms are similar to those in patients with GBS, MFS, and MMN, respectively, and serum anti-ganglioside antibodies were found to be positive in all patients. Using magnetic and electrical stimulation techniques, central and peripheral motor conduction were compared in patients in groups 1, 2, and 3 and patients with GBS (n=7), MFS (n=8), and MMN (n=6).
RESULTS: Central motor conduction times (CMCTs) in patients in groups 1, 2, and 3 were significantly delayed compared with those in patients with GBS, MFS, and MMN (p<0.01, p<0.05, p<0.05, respectively), and the delayed CMCTs significantly improved in the recovery periods (p<0.01, p<0.01, p<0.05, respectively). However, motor conduction velocity, compound muscle action potential, and F wave conduction velocity were not significantly different between the patients.
CONCLUSION: These findings indicate that corticospinal tract is functionally involved in patients with anti-ganglioside antibody associated neuropathy syndromes and hyperreflexia

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12397153      PMCID: PMC1738137          DOI: 10.1136/jnnp.73.5.568

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  33 in total

1.  A clinicopathological study of the Guillain-Barré syndrome. Nine cases and literature review.

Authors:  M Honavar; J K Tharakan; R A Hughes; S Leibowitz; J B Winer
Journal:  Brain       Date:  1991-06       Impact factor: 13.501

Review 2.  Assessment of current diagnostic criteria for Guillain-Barré syndrome.

Authors:  A K Asbury; D R Cornblath
Journal:  Ann Neurol       Date:  1990       Impact factor: 10.422

3.  Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates.

Authors:  A Pestronk; R Choksi
Journal:  Neurology       Date:  1997-11       Impact factor: 9.910

4.  Corticospinal tract involvement in a variant of Guillain-Barré syndrome.

Authors:  Y Oshima; T Mitsui; I Endo; Y Umaki; T Matsumoto
Journal:  Eur Neurol       Date:  2001       Impact factor: 1.710

5.  Hyperreflexia in Guillain-Barré syndrome: relation with acute motor axonal neuropathy and anti-GM1 antibody.

Authors:  S Kuwabara; K Ogawara; M Koga; M Mori; T Hattori; N Yuki
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-08       Impact factor: 10.154

6.  A syndrome of asymmetric limb weakness with motor conduction block.

Authors:  C Krarup; J D Stewart; A J Sumner; A Pestronk; S A Lipton
Journal:  Neurology       Date:  1990-01       Impact factor: 9.910

7.  Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside.

Authors:  H J Willison; J Veitch; G Paterson; P G Kennedy
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-02       Impact factor: 10.154

Review 8.  Multifocal motor neuropathy: diagnosis and treatment.

Authors:  A Pestronk
Journal:  Neurology       Date:  1998-12       Impact factor: 9.910

9.  Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies.

Authors:  A Chiba; S Kusunoki; H Obata; R Machinami; I Kanazawa
Journal:  Neurology       Date:  1993-10       Impact factor: 9.910

10.  Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.

Authors:  R D Hadden; D R Cornblath; R A Hughes; J Zielasek; H P Hartung; K V Toyka; A V Swan
Journal:  Ann Neurol       Date:  1998-11       Impact factor: 10.422

View more
  3 in total

1.  Yet Another Atypical Presentation of Anti-GQ1b Antibody Syndrome.

Authors:  Raed Alroughani; Anil Thussu; Raouf T Guindi
Journal:  Neurol Int       Date:  2015-09-24

2.  Asymmetrical weakness associated with central nervous system involvement in a patient with guillain-barrè syndrome.

Authors:  Takao Kiriyama; Makito Hirano; Susumu Kusunoki; Daiji Morita; Minako Hirakawa; Yasuyo Tonomura; Takanori Kitauchi; Satoshi Ueno
Journal:  Clin Med Case Rep       Date:  2009-09-03

3.  Dysfunction of Corticomotoneurons in Guillain-Barré Syndrome (GBS)?

Authors:  Steve Vucic
Journal:  Clin Med Case Rep       Date:  2009-10-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.